For the more than 12,000 patients, clinicians and members of the public who took part in a year-long national conversation about artificial intelligence in healthcare, the message they sent has now been answered in full. On 6 October 2026, the government confirmed it will accept all 44 recommendations of the National Commission into the Regulation of AI in Healthcare, the independent body led by NHS doctors whose report was published on 10 September.
That engagement, described as the largest of its kind on the regulation of healthcare technology, was shaped by people like the patients Professor Henrietta Hughes heard from in her role as Deputy Chair of the Commission and Patient Safety Commissioner for England. “Patients have told us they want artificial intelligence that improves care without compromising safety, transparency or accountability,” she said. She welcomed the commitment to monitoring AI throughout its use in practice, strengthening patient involvement in decision-making, and ensuring there are clear routes to redress when things go wrong. “Patients must remain at the heart of how these technologies are developed, regulated and used across healthcare,” she added.
What the response means in practice is a shift in how the technologies reaching hospital wards and GP surgeries are judged. The Commission concluded that the current regulatory approach must evolve, moving away from over-reliance on one-time assessments towards a proportionate, lifecycle-based framework in which AI-enabled medical devices are assessed and monitored throughout their working life. The aim, ministers say, is that patients can benefit from safe, effective and trusted AI more quickly, while robust safeguards keep pace as the technology changes.
Putting that principle to work starts immediately. Alongside the response, the Medicines and Healthcare products Regulatory Agency is opening applications for the third phase of AI Airlock, its regulatory sandbox for AI-enabled medical devices, backed by three years of additional government funding after a successful pilot and Phase 2 programme. Phase 3 will focus specifically on post-market surveillance and lifecycle regulation, working with real products to test how devices can be safely monitored and managed once deployed. Eligible developers can apply now, with full details at https://www.gov.uk/government/news/government-backs-recommendations-of-nhs-doctors-led-ai-commission, and a webinar for prospective applicants on 22 October 2026 at 10:00. The first wave of innovators will be selected in November 2026, when applications close.
Meanwhile, further steps are set out in a timetable that officials hope will give both patients and developers clarity. The MHRA has committed to issuing draft guidance by December 2026 on managing changes to AI-enabled devices as they adapt and improve over time. Next year it will consult on how to qualify and classify AI-enabled devices, the Commission’s first recommendation. Other commitments include exploring staged authorisation pathways, allowing promising AI tools to be used in the NHS earlier under close supervision while further real-world evidence is gathered. A full implementation roadmap covering all 44 recommendations will be published by Spring 2027, with regular progress updates to follow.
The government has also promised to work with partners across the health system to strengthen patient engagement in decision-making, improve access to redress where standards of care fall below expectations, and ensure the benefits of AI are shared fairly across all communities, including underserved groups. A newly established Programme Board will convene with work already under way across government, the MHRA, NHS partners and the devolved authorities on nine priority areas.
Health Innovation Minister James Frith framed the changes around the people they are meant to serve. “We want all patients to benefit from the life-saving potential of AI, with the confidence that it is safe, effective and properly overseen,” he said, adding that the NHS should harness new technologies to give patients faster, better care and give staff more time to focus on patients. “But innovation must never come at the expense of patient safety.”
Lawrence Tallon, the MHRA’s Chief Executive, said the Commission, led by NHS doctors, had given a clear and ambitious blueprint for making the UK the best place to get AI products to patients safely, quickly and in a way that maintains public trust. Professor Alastair Denniston, the Commission’s Chair, said the response showed government had listened not just to the Commission but to the 12,000 people who shaped its recommendations, and pointed to AI Airlock Phase 3 as an early sign of the lifecycle-based approach in action from day one.
Devolved ministers echoed that welcome. Mabon ap Gwynfor, Wales’ Cabinet Minister for Health and Care, said patients stand to benefit from a regulatory system that is safer, faster and more trusted. Northern Ireland Health Minister Robbie Butler said he was particularly pleased that Northern Ireland’s perspectives were reflected throughout the work. Scottish Health Secretary Angela Constance said Scotland shares the Commission’s ambition and will set out its own response in due course, noting interim guidance already in place and a commitment to developing an AI Hub for safe adoption.
For patients, the test of these reforms will be whether AI reaches their care in a way that feels trustworthy rather than imposed. The Commission’s guiding principles, described by Denniston as people-centred, safe, fast and trusted, are now the standard against which delivery will be judged, and the roadmap due by Spring 2027 will show whether that promise holds.